ARTICLE | Company News
Prev AbR LLC, Synthetic Biologics deal
November 19, 2012 8:00 AM UTC
Synthetic will acquire from Prev products targeting beta-lactamase to prevent Clostridium difficile infection. Prev received $100,000 up front, and will receive $135,000 in cash and 625,000 Synthetic ...